Sleep management specialist ResMed Inc (ASX: RMD) said on Friday that it achieved record revenue and income for the financial year 2009/10, reporting an operating income of $US240.4 million and a net income of $US190.1 million for the 12 months leading to June 30

The company said that both upward movements were reflective of the 26 percent and 30 percent respective gains on both the operation and net income as against the figures posted in the previous financial year, while its 2010 revenue reached a total of $US1.1 billion, which is a 19 percent climb from 2009 or 17 percent on a constant currency basis.

ResMed chief executive Kieran Gallahue hailed the company's impressive figures, stressing that "surpassing the billion dollar mark in annual sales is a result of our ability to continue to innovate and launch new products to treat sleep-disordered breathing."

Mr Gallahue is upbeat that the growth would be further sustained as medical breakthroughs pointed to "the increasing confirmation of the strong impact of the relationship between sleep-disordered breathing, obstructive sleep apnea and co-morbidities such as cardiac disease, diabetes, hypertension and obesity."

Also, the company announced that its board of directors had given the go signal for a two-for-one stock split of the company's outstanding shares of common stock, which ResMed added would be payable in the form of a hundred percent stock dividend.

Mr Gallahue explained that the stock split was decided in consideration of the best interest of the company's shareholders as he underscored that "ResMed has delivered an outstanding return for our shareholders, and the split is designed to improve liquidity and broaden ownership in our company.

As of 1141 AEST on Friday, ResMed shares were trading at $7.19, which is 18 cents lower from the stocks' previous high.